Peptide Monograph

Kisspeptin-10

Kisspeptin / Metastin (KISS1 Gene Product Fragment)

At a Glance

Mechanism of Action

Kisspeptin-10 is a biologically active C-terminal decapeptide fragment of the full-length kisspeptin protein (also known as metastin), which is encoded by the KISS1 gene. The KISS1 gene was originally identified as a metastasis-suppressor gene, but its pivotal role in reproductive endocrinology was established when loss-of-function mutations in its receptor, KISS1R (formerly GPR54), were found to cause hypogonadotropic hypogonadism in humans.[1]

Kisspeptin-10 binds to the KISS1R receptor (GPR54), a G-protein-coupled receptor expressed on gonadotropin-releasing hormone (GnRH) neurons in the hypothalamus. Activation of KISS1R potently stimulates the release of GnRH into the hypophyseal portal circulation, which in turn triggers the anterior pituitary to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH).[2] This positions kisspeptin as the master upstream regulator of the hypothalamic-pituitary-gonadal (HPG) axis.

The kisspeptin-GnRH-gonadotropin cascade is the principal mechanism through which the brain controls reproductive function. Kisspeptin neurons integrate metabolic, circadian, and stress-related signals to modulate GnRH pulsatility. Kisspeptin signaling is essential for puberty onset, as demonstrated by the failure to enter puberty in individuals with inactivating KISS1 or KISS1R mutations.[1]

Kisspeptin also plays a critical role in pregnancy implantation. Kisspeptin levels rise dramatically during pregnancy (up to 7,000-fold increase), and the peptide is expressed in placental trophoblast cells where it is thought to regulate trophoblast invasion and placentation.[3]

Importantly, kisspeptin stimulates GnRH release in a physiological pulsatile manner, which distinguishes it from continuous GnRH agonists that cause receptor desensitization and eventual suppression of gonadotropins. This property has generated significant interest in kisspeptin as a more physiological trigger for oocyte maturation in IVF protocols, potentially reducing the risk of ovarian hyperstimulation syndrome (OHSS).[4]

Evidence Summary

Human Studies

Dhillo et al. (2005) conducted the seminal human study demonstrating that intravenous kisspeptin-10 potently stimulated LH and FSH secretion in healthy male volunteers. A single IV bolus of kisspeptin-10 produced a rapid and robust increase in circulating LH and FSH levels, establishing for the first time that exogenous kisspeptin activates the reproductive axis in humans.[2]

Jayasena et al. extended these findings in a series of studies demonstrating that kisspeptin-10 stimulates gonadotropin release in both men and women across various reproductive states. In women with functional hypothalamic amenorrhea (a condition characterized by suppressed GnRH pulsatility due to stress, weight loss, or exercise), kisspeptin administration restored LH pulsatility, suggesting therapeutic potential for this common cause of infertility.[3]

Abbara et al. conducted Phase 2 clinical trials investigating kisspeptin as an alternative to human chorionic gonadotropin (hCG) for triggering oocyte maturation in IVF cycles. Kisspeptin triggered oocyte maturation effectively while producing a significantly lower risk of ovarian hyperstimulation syndrome (OHSS), a potentially life-threatening complication of IVF. This represents the most clinically advanced application of kisspeptin.[4]

Foundational Research

The discovery of kisspeptin's role in reproduction was established independently by de Roux et al. and Seminara et al. in 2003, who identified that loss-of-function mutations in GPR54 (KISS1R) caused idiopathic hypogonadotropic hypogonadism, definitively linking kisspeptin signaling to the control of puberty and fertility.[1][5]

Primary Uses (in Research)

Based on the available clinical and preclinical literature, kisspeptin-10 has been investigated for the following applications:

• IVF oocyte maturation trigger — As an alternative to hCG for triggering final oocyte maturation in IVF, with a potentially lower risk of OHSS. This is the most clinically advanced application with Phase 2 data.[4]
• Functional hypothalamic amenorrhea — Restoration of GnRH pulsatility and gonadotropin release in women with stress- or exercise-induced hypothalamic suppression.[3]
• Hypogonadotropic hypogonadism — Stimulation of the reproductive axis in individuals with deficient GnRH secretion, including as a diagnostic tool.[2]
• Diagnostic testing — As a provocative test to assess hypothalamic-pituitary-gonadal axis integrity (kisspeptin stimulation test).[2]
• Male reproductive function — Investigation of kisspeptin's ability to stimulate testosterone production via the LH axis in men with low testosterone.[2]

Contraindications

Standard Protocols

Common Stacks & Synergies

Kisspeptin is primarily investigated as a standalone agent in clinical research settings. Unlike many other peptides in the self-experimentation community, kisspeptin stacking protocols are largely derived from clinical research rather than community practice:

• Kisspeptin + GnRH (research context) — Sequential administration to differentiate hypothalamic from pituitary causes of hypogonadism. Kisspeptin tests hypothalamic GnRH neuron responsiveness, while exogenous GnRH tests pituitary responsiveness.
• Kisspeptin in IVF protocols — Used as a trigger in combination with standard IVF stimulation protocols (FSH/hMG), replacing hCG as the final maturation trigger to reduce OHSS risk.[4]
• Kisspeptin + Clomiphene (theoretical) — Some researchers have discussed combining kisspeptin with selective estrogen receptor modulators for synergistic HPG axis stimulation, though no published data supports this combination.

Preparation & Administration

Kisspeptin-10 is supplied as a lyophilized (freeze-dried) powder. It must be reconstituted with bacteriostatic water or sterile saline before injection. The very short half-life (~28 minutes) is a key consideration for dosing timing and route selection.

Reconstitution

Reconstitution follows standard peptide preparation procedures. The concentration should be calculated based on the specific dosing protocol being followed. Due to the weight-based dosing used in clinical research (mcg/kg), accurate body weight measurement and precise reconstitution are essential. For detailed step-by-step reconstitution instructions and a concentration calculator, see the Reconstitution Guide.

Injection

In clinical research, kisspeptin-10 has been administered via both intravenous bolus and subcutaneous injection. IV administration produces a more rapid and pronounced gonadotropin response. Subcutaneous injections should be administered using a 29–31 gauge insulin syringe. For injection technique, site selection, and sterile procedure, see the Injection Safety Guide.

Side Effects & Adverse Events

In published clinical studies, kisspeptin-10 has been generally well-tolerated at the doses tested. Dhillo et al. and Jayasena et al. reported no serious adverse events in their human studies at doses up to 10 mcg/kg IV.[2][3]

Reported side effects from clinical studies and self-reports:

• Headache (most commonly reported)
• Nausea (mild, transient)
• Hot flushes, consistent with acute gonadotropin and sex hormone release
• Injection site reactions (redness, mild pain)
• Transient abdominal discomfort
• Flushing (facial)

The acute hormonal effects of kisspeptin (rapid LH/FSH surge followed by sex hormone release) are expected pharmacological effects rather than adverse events per se, but may produce noticeable symptoms in some individuals.

Drug Interactions

No formal drug interaction studies have been conducted with kisspeptin-10. The following theoretical interactions are based on the peptide's potent effects on the HPG axis:

• GnRH agonists/antagonists (leuprolide, cetrorelix) — Kisspeptin acts upstream of GnRH. GnRH antagonists would block kisspeptin's downstream effects, while GnRH agonists could produce additive stimulation followed by desensitization.
• Hormonal contraceptives — Combined oral contraceptives suppress the HPG axis through negative feedback. Kisspeptin's ability to override this suppression is uncertain and could produce unpredictable hormonal effects.
• Anti-androgens and anti-estrogens — Drugs like tamoxifen, letrozole, or enzalutamide that modify sex hormone signaling could interact with kisspeptin-induced gonadotropin release. Clomiphene and letrozole may have additive effects on LH release.
• Exogenous testosterone or estrogen — Exogenous sex hormones suppress endogenous GnRH pulsatility. The interaction with exogenous kisspeptin in this context is not well characterized.
• Dopamine agonists (cabergoline, bromocriptine) — Dopamine modulates GnRH and LH release. Interactions with kisspeptin are theoretically possible.

Storage & Handling

Do not freeze reconstituted solution. Protect from prolonged light exposure. If the solution appears cloudy, discolored, or contains particulate matter, discard the vial. Always use bacteriostatic water (not sterile water) for reconstitution to provide antimicrobial preservation for multi-dose use.

Legal & Regulatory Status

• FDA (United States) — Not approved for any therapeutic indication. Active investigational research, particularly in fertility. No IND status has been publicly disclosed for US trials as of this writing.
• Clinical trial status — Multiple Phase 1 and Phase 2 clinical trials have been completed or are ongoing, primarily at Imperial College London and affiliated institutions. Research is focused on IVF applications and reproductive disorders.
• WADA (World Anti-Doping Agency) — Not specifically listed on the WADA Prohibited List as of 2026. Given its ability to stimulate testosterone production via LH, it could potentially be considered under S2 (peptide hormones) depending on interpretation.
• European Union — Not approved as a medicinal product. Investigational use in clinical trials.
• General status — Kisspeptin-10 is available as a research chemical. It is not legal to market for human therapeutic use in any jurisdiction.

Open Questions

Despite being one of the more actively researched peptides, significant questions remain:

• Optimal route and dosing for chronic use — The very short half-life (~28 minutes) makes kisspeptin-10 impractical for chronic dosing without repeated injections or continuous infusion. Longer-acting analogs are under development.
• Tachyphylaxis with repeated dosing — Whether repeated kisspeptin administration leads to desensitization of the KISS1R receptor and diminished gonadotropin response over time is not fully characterized.
• IVF trigger optimization — While Phase 2 data is promising, the optimal dose and timing of kisspeptin as an IVF trigger, and whether it produces comparable pregnancy rates to hCG, requires Phase 3 confirmation.
• Male hypogonadism application — Whether kisspeptin can serve as a sustainable treatment for male hypogonadism (as an alternative to testosterone replacement) given its short half-life and potential for desensitization is unknown.
• Long-acting analogs — Development of kisspeptin analogs with extended half-lives could dramatically expand clinical utility, but none have advanced to clinical trials as of this writing.
• Cancer interactions — The KISS1 gene was originally identified as a metastasis suppressor, yet kisspeptin stimulates sex hormones that can fuel hormone-sensitive cancers. The net effect of exogenous kisspeptin on cancer biology requires further investigation.

Bibliography

1. de Roux N, Genin E, Carel JC, Matsuda F, Chaussain JL, Milgrom E. "Hypogonadotropic hypogonadism due to loss of function of the KiSS1-derived peptide receptor GPR54." Proc Natl Acad Sci U S A. 2003;100(19):10972-6. doi:10.1073/pnas.1834399100. PMID:12944565.
2. Dhillo WS, Chaudhri OB, Patterson M, Thompson EL, Murphy KG, Badman MK, McGowan BM, Amber V, Patel S, Ghatei MA, Bloom SR. "Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males." J Clin Endocrinol Metab. 2005;90(12):6609-15. doi:10.1210/jc.2005-1468. PMID:16174713.
3. Jayasena CN, Nijher GM, Chaudhri OB, Murphy KG, Ranger A, Lim A, Patel D, Mehta A, Todd C, Ramachandran R, Salem V, Stamp GW, Donaldson M, Ghatei MA, Bloom SR, Dhillo WS. "Subcutaneous injection of kisspeptin-54 acutely stimulates gonadotropin secretion in women with hypothalamic amenorrhea, but chronic administration causes tachyphylaxis." J Clin Endocrinol Metab. 2009;94(11):4315-23. doi:10.1210/jc.2009-0406. PMID:19820030.
4. Abbara A, Clarke S, Islam R, Prague JK, Comninos AN, Salber S, Sherber HS, Ghai J, Sherber HS, Jayasena CN, Christopoulos G, Vnuk A, Wilber HN, Marquis TJ, Nawroth F, Muller A, Trew GH, Dhillo WS. "A second dose of kisspeptin-54 improves oocyte maturation in women at high risk of ovarian hyperstimulation syndrome: a Phase 2, randomized, placebo-controlled trial." Hum Reprod. 2017;32(9):1915-1924. doi:10.1093/humrep/dex253. PMID:28854590.
5. Seminara SB, Messager S, Chatzidaki EE, Thresher RR, Acierno JS Jr, Shagoury JK, Bo-Abbas Y, Kuohung W, Schwinof KM, Hendrick AG, Zahn D, Dixon J, Kaiser UB, Slaugenhaupt SA, Gusella JF, O'Rahilly S, Carlton MB, Crowley WF Jr, Aparicio SA, Colledge WH. "The GPR54 gene as a regulator of puberty." N Engl J Med. 2003;349(17):1614-27. doi:10.1056/NEJMoa035322. PMID:14573733.